BiomX Inc(PHGE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -216.64 | Insider Own | 15.96% | Shs Outstand | 2.7M | Perf Week | 29.82% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | -79.45% | Shs Float | 2.3M | Perf Month | 16.5% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | - | Inst Own | 2.61% | Short Float | 1.52% | Perf Quarter | -71.08% |
| Income | -0.05B | P/S | 14.99 | EPS this Y | - | Inst Trans | 2.34% | Short Ratio | 0.11 | Perf Half Y | -97.04% |
| Sales | 0.00B | P/B | 0.5 | EPS next 5Y | - | ROA | -136.51% | Short Interest | 0.03M | Perf YTD | -90.11% |
| Book/sh | 3.7 | P/C | 8.68 | EPS past 3/5Y | 50.25% 38.28% | ROE | -299.52% | 52W High | -98.5% ($122.93) | Perf Year | -97.9% |
| Cash/sh | 0.21 | P/FCF | - | Sales past 3/5Y | - | ROIC | -397.51% | 52W Low | 55.2% ($1.19) | Perf 3Y | -99.76% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -12.54% | Gross Margin | -691.87% | Volatility(W/M) | 11.67% 7.88% | Perf 5Y | -99.97% |
| Dividend TTM | - | EV/Sales | 63.69 | Sales Y/Y TTM | - | Oper. Margin | -6759.34% | ATR (14) | 0.2 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.24 | EPS Q/Q | 90.02% | Profit Margin | -13704.82% | RSI (14) | 58.02 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.24 | Sales Q/Q | - | SMA20 | 28.41% ($1.44) | Beta | 1.26 | Target Price | $3990 |
| Payout | - | Debt/Eq | 0.3 | Earnings | 2026/04/01 | SMA50 | -0.11% ($1.85) | Rel Volume | 10.24 | Prev Close | $1.62 |
| Employees | 20 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | 1.69% - | SMA200 | -91.83% ($22.64) | Avg Volume(3M) | 0.32M | Price | $1.85 |
| IPO | 2019/3/13 | Option/Short | No/Yes | Trades | 9357 | Volume | 3,254,400 | Change | 14.2% |
🧬 BiomX (ticker not specified) is a clinical-stage biotech developing precision antibacterial therapies based on natural and genetically engineered bacteriophages. BX211, for diabetic foot osteomyelitis (DFO), demonstrated a meaningful reduction in ulcer size compared with placebo in a Phase 2 trial, while BX004, targeting chronic Pseudomonas aeruginosa infections in cystic fibrosis (CF) patients, is currently in a Phase 2b clinical trial. The company's approach is distinguished by addressing the key weaknesses of conventional antibiotics—namely, antibiotic resistance and biofilm formation.
Over the past 1 year, on the lower side
98% below its 1-year high.
Traded more than usual. That is 1024% of its average volume.
PHGE has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,499. Peers typically go for $344.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +64% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 2.6%.
Tap to view numbers
It ranks #94 of 97 in the industry
Based on market cap of $5M.
FAQ
What kind of company is PHGE?
PHGE belongs to the Industrials sector and operates in the Aerospace & Defense industry.
What is the market cap of PHGE?
The market cap of PHGE is approximately $5M, ranking 5,687 within its sector.
What is the 52-week high and low for PHGE?
PHGE has recorded a 52-week high of $122.93 and a low of $1.19.
